Connection

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Van Rhee, Frits

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item Type	Name
Academic Article	Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Academic Article	DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Academic Article	Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Academic Article	Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Academic Article	High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Academic Article	Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Academic Article	Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Academic Article	Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Academic Article	Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Academic Article	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Academic Article	Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Academic Article	Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
Academic Article	Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Academic Article	Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Academic Article	Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Academic Article	Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.
Academic Article	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Academic Article	Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Academic Article	First thalidomide clinical trial in multiple myeloma: a decade.
Academic Article	Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Academic Article	International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Concept	Thalidomide
Academic Article	First thalidomide clinical trial in multiple myeloma: a decade later
Academic Article	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.
Academic Article	Storming the Castle with TCP.

Search Criteria

Thalidomide